3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Breast
1
Conditions
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Prostatic Neoplasms
1
Multiple Myeloma
1
Leukemia, Myeloid
1
Leukemia, Monocytic, Acute
1
Leukemia, Lymphoid
1
Leukemia
1
Kidney Neoplasms
1
Hodgkin Disease
1
Drug-Related Side Effects and Adverse Reactions
1
Cardiovascular Diseases
1
Cardiotoxicity
1
Interventions
Cyclophosphamide
3
Pyridoxine
2
Amifostine
2
trastuzumab deruxtecan
1
sodium thiosulfate
1
sargramostim
1
sacituzumab govitecan
1
eribulin
1
Triptorelin Pamoate
1
Trastuzumab
1
Thiotepa
1
Social Determinants of Health
1
Radiotherapy
1
Pregabalin
1
Peripheral Blood Stem Cell Transplantation
1
Mitoxantrone
1
Methotrexate
1
Furosemide
1
Etoposide
1
Epoetin Alfa
1
Duloxetine Hydrochloride
1
Drug Therapy
1
Doxorubicin
1
Dihydrouracil Dehydrogenase (NADP)
1
Cisplatin
1
Chemotherapy, Adjuvant
1
Celecoxib
1
Carboplatin
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Drug-Related Side Effects and Adverse Reactions
×
Social Determinants of Health
×
Breast
×
Clear all
NCT05078190
2025-11-06
CCT2
Abramson Cancer Center at Penn Medicine
Active not recruiting
200 enrolled